Focused On-demand Libraries - Receptor.AI Collaboration
Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
- The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
- Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
- Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
- Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.
Receptor.AI
Q8IVL1
UPID:
NAV2_HUMAN
ALTERNATIVE NAMES:
Helicase APC down-regulated 1; Pore membrane and/or filament-interacting-like protein 2; Retinoic acid inducible in neuroblastoma 1; Steerin-2; Unc-53 homolog 2
ALTERNATIVE UPACC:
Q8IVL1; A6NEC1; Q8IVK3; Q8IVK4; Q8IVK5; Q8IVK6; Q8IVK7; Q8IVK8; Q8NHC9; Q8NHD0; Q8TDE9; Q8TDF0; Q8TEB3; Q96B30; Q9NUZ6; Q9NVM7; Q9P2C8